| 翻訳と辞書 |
Tigatuzumab
Tigatuzumab (CS-1008) is a monoclonal antibody〔(WHO Drug Information )〕 for the treatment of cancer. , a clinical trial for the treatment of pancreatic cancer has been completed,〔NCI: (Combination Therapy Targets Pancreatic Cancer Stem Cells )〕 Phase II trials for colorectal cancer〔NCI: (CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin )〕 and non-small cell lung cancer〔NCI: (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC) )〕 are running, and a study for ovarian cancer has been approved.〔NCI: (Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer )〕
The drug targets member 10b of the tumor necrosis factor receptor superfamily (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein overexpressed in many kinds of tumour.〔NCI: (CS-1008 )〕
A recent study reports on the preclinical validation of 111In-labeled anti-DR5 humanised antibody CS-1008 as a diagnostic tool to study the DR5 occupancy in cancer patients, and establish dose ranges for receptor saturation kinetics in vivo.〔http://clincancerres.aacrjournals.org/content/early/2013/09/17/1078-0432.CCR-12-3104.abstract〕
== References ==
〔
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Tigatuzumab」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|